Search

Kymera Therapeutics Inc

Открыт

СекторЗдравоохранение

105.26 -2.72

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

103.83

Макс.

107.97

Ключевые показатели

By Trading Economics

Доход

8M

-61M

Продажи

31M

65M

Прибыль на акцию

-0.62

Рентабельность продаж

-94.171

Сотрудники

273

EBITDA

8.1M

-59M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+30.85% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

968M

9.2B

Предыдущая цена открытия

107.98

Предыдущая цена закрытия

105.26

Kymera Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

15 окт. 2026 г., 20:02 UTC

Correlated Moves

Kymera Therapeutics Inc shares are advancing, supported by high trading volume, while Nurix Therapeutics Inc rises sharply following a director's stock sale.

13 окт. 2026 г., 20:01 UTC

Kymera Therapeutics Inc shares are declining, diverging from recent gains, amid high trading volume and broader weakness in the biotechnology sector.

9 окт. 2026 г., 20:07 UTC

Social Media
News

Raymond James initiated coverage on Kymera Therapeutics Inc with an Outperform rating and set a price target of $140.

8 окт. 2026 г., 20:07 UTC

Kymera Therapeutics Inc shares are modestly higher, recovering from a notable low earlier in the day, but remain below their 20-day moving average.

7 окт. 2026 г., 20:12 UTC

Kymera Therapeutics Inc is trading lower during after-market hours, reflecting a cumulative return of -1.14% since Wednesday's close and remaining below its 20-day moving average.

6 окт. 2026 г., 20:00 UTC

Kymera Therapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes, amid unusually high trading volume.

5 окт. 2026 г., 19:51 UTC

Social Media
News

Kymera Therapeutics shares rise as Citigroup maintains a Buy rating and raises the price target to $150, reflecting confidence in growth potential.

2 окт. 2026 г., 20:01 UTC

News

Kymera Therapeutics Inc. shares fell sharply amid significant insider transactions, including CEO Nello Mainolfi's sale of 30k shares, reflecting ongoing weakness.

1 окт. 2026 г., 19:45 UTC

Kymera Therapeutics Inc shares fell modestly, currently below the 20-day moving average and near the lower end of its one-month trading range.

30 сент. 2026 г., 20:03 UTC

Kymera Therapeutics Inc is advancing today with increased trading volume, despite earlier pulling back from a session high, amid broader market gains since Tuesday.

29 сент. 2026 г., 21:01 UTC

Kymera Therapeutics Inc is seeing higher after-market trading, shifting from a slight loss to a notable gain amid broader market trends and rising bond yields.

28 сент. 2026 г., 20:01 UTC

Kymera Therapeutics Inc is seeing increased trading activity today, reaching a peak return since Friday, despite remaining below its 20-day moving average.

25 сент. 2026 г., 20:07 UTC

Correlated Moves

Kymera Therapeutics Inc shares fell amid a broader market decline, reflecting significant weakness in the biotechnology sector and sympathy with Hyperliquid Strategies Inc.

24 сент. 2026 г., 20:07 UTC

News

Kymera Therapeutics Inc's shares are modestly higher, rebounding to close above Wednesday's level despite remaining below its 20-day moving average.

23 сент. 2026 г., 20:02 UTC

Kymera Therapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes amid unusually high trading volume.

22 сент. 2026 г., 20:07 UTC

News

Stifel reiterated its Buy rating on Kymera Therapeutics and raised the price target to $152, with shares trading higher amid strong momentum.

18 сент. 2026 г., 20:06 UTC

Kymera Therapeutics Inc shares fell sharply, pulling back from Thursday's close and reaching a low in late afternoon trading after a brief rise earlier in the session.

17 сент. 2026 г., 20:07 UTC

Kymera Therapeutics Inc is advancing during Thursday's market session, having reached a session high earlier before pulling back from that peak.

16 сент. 2026 г., 20:10 UTC

Social Media

Kymera Therapeutics Inc is trading higher as interest grows due to faster-than-expected enrollment in the Phase 2b BROADEN2 study for its drug KT-621.

15 сент. 2026 г., 23:31 UTC

Kymera Therapeutics Inc shares are lower in after-market hours, continuing a four-session decline amid broader economic concerns from the NY Empire State Manufacturing Index drop.

11 сент. 2026 г., 19:52 UTC

Kymera Therapeutics Inc is lower today, pulling back from earlier gains amid speculation about Federal Reserve interest rate hikes and broader market trends.

10 сент. 2026 г., 20:07 UTC

News
Social Media

Wolfe Research upgraded Kymera Therapeutics to Outperform, setting a price target of $180. Shares are trading higher amid increased investor interest.

9 сент. 2026 г., 20:07 UTC

Kymera Therapeutics Inc shares are lower Wednesday, reflecting broader market pressures amid rising crude oil prices and inflation concerns.

8 сент. 2026 г., 20:07 UTC

News

Kymera Therapeutics shares are lower amid insider selling, including a recent sale by Brian Adams. The stock has seen a cumulative decline since Friday.

2 сент. 2026 г., 19:46 UTC

Event
News

Shares rise as JPMorgan raises price target to $140.00.

28 авг. 2026 г., 20:01 UTC

Kymera Therapeutics Inc shares are lower today, continuing a decline since Thursday. Trading volume is unusually high amid rising U.S. Treasury yields.

27 авг. 2026 г., 20:02 UTC

News

Kymera Therapeutics Inc shares are lower today, diverging from recent gains amid high trading volume and broader market resilience following a drop in jobless claims.

25 авг. 2026 г., 20:07 UTC

Kymera Therapeutics shares are higher today, supported by declining oil prices and lower Treasury yields, enhancing overall investor sentiment toward equities.

21 авг. 2026 г., 19:26 UTC

News
Social Media

Kymera Therapeutics Inc shares are lower during Friday's session despite earlier gains. Analysts maintain a consensus "Moderate Buy" rating with a target of $125.65.

20 авг. 2026 г., 22:01 UTC

Kymera Therapeutics Inc. shares are higher in after-market trading, supported by a broader upward trend in biotechnology stocks. The price remains above its 20-day moving average.

Сравнение c конкурентами

Изменение цены

Kymera Therapeutics Inc Прогноз

Целевая цена

By TipRanks

30.85% рост

Прогноз на 12 месяцев

Средняя 141.5 USD  30.85%

Максимум 180 USD

Минимум 112 USD

Основано на мнении 16 аналитиков Wall Street, спрогнозировавших целевые цены для Kymera Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

16 ratings

14

Покупка

2

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat